Fig. 3

CKD progression in matched spironolactone users and non-users stratified by CKD stage at inclusion. (A) Proportion of patients who experienced progression to a more advanced stage of kidney disease (higher CKD stage, ESRD or renal replacement therapy) by 1 year post-inclusion. (B) Kaplan–Meier plots showing CKD progression in the matched cohorts during the post-inclusion period. CKD, chronic kidney disease; ESRD, end-stage renal disease